• Secondary hyperparathyroidism developed on two separate occasions in a patient taking an oral contraceptive (OC) in a mixture of norethindrone and mestranol (Ortho-Novum 1/80). The probable cause of this condition is an estrogenic inhibition of the calcium mobilizing effect of parathyroid hormone (PTH) or vitamin D. The possible consequences of OC therapy in this patient and patients like her include those of milk hypocalcemia, moderate hypophosphatemia, or the neurotoxic actions of excessive levels of circulating PTH. One should also consider the possible role of OC therapy in patients with unexplained parathyroid hyperplasia and with tertiary hyperparathyroidism.
(Arch Intern Med 1982;142:128-129)
Moses AM, Notman DD. Secondary Hyperparathyroidism Caused by Oral Contraceptives. Arch Intern Med. 1982;142(1):128–129. doi:10.1001/archinte.1982.00340140130020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: